ClinicalTrials.gg
Status unknownNCT03850834Updated Feb 22, 2019

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject

A Phase 1 interventional study of Ammoxetine Hydrochloride Enteric-coated Tablets and placebo enteric-coated tablets in Depression, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-22.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese healthy subjects

02

Conditions studied

  • Depression

Browse trials for

03

In context

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

This study's planned enrollment of 36 is below the median of 81 across 7,078 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females age 18-45 years
  • Body weight ≥ 45kg (female) or 50Kg (male), 18 ≤ ≤ 26
  • Vital signs, physical examinations and laboratory tests and other tests prove participants are healthy
  • Sign the form voluntarily and cooperate voluntarily to complete the test

Exclusion criteria

Exclusion Criteria:

  • Allergens (allergic to 2 or more drugs, food or pollen)
  • comorbid illness (mental illness, liver and kidney disease, gastrointestinal diseases, nervous system disease, or other systemic diseases)
  • have abnormal screening laboratory values.
  • Systolic pressure > 140mmHg or diastolic > 90 mmHg
  • Postural hypotension (systolic blood pressure drop by 20mmHg or diastolic blood pressure drop by 10mmHg after standing position)
  • The period ≥ 450ms (male) or 470ms (female) or has a history of QTc extension
  • Smoking or alcohol consumption (14 units per week in the previous 4 weeks : 1 unit = beer 285mL, or 25mL of spirits, or 150 mL of wine; Daily smoking ≥ 5) or abusing in past year of drug and other substance
  • Have donated or lost blood 400 ml within 8 weeks prior to screening
  • Participated in other clinical trials within 3 months prior to screening
  • Intakes too much caffeinated beverage or food within 4 weeks prior to screening. such as: Coffee, tea, chocolate, cola, red bull (no more than 6 units per day). 1 unit of caffeine = 1 cup of coffee (177.4 mL) = 2 pots of cola (354.9 mL) = 1 cup of tea (354.9 mL) = 1/2 cup energy drink = 85g chocolate
  • Have taken drugs that changed liver enzyme activity, such as dexamethasone, ketoconazole, rifampicin and omeprazole, were used within 4 weeks prior to screening
  • Have taken prescription drugs and OTC (except for the occasional use of acetaminophen and nasal sprays), herbs vitamins or minerals within 4 weeks prior to screening. The interval from prior treatment to screening should be at least 5 half-lives metablism which subjected to the longer halflife
  • Using any psychotropic drug or psychoactive substance
  • Women were screened for positive blood pregnancy
  • The subjects and their partners were not willing to take during trial and six months after the study
  • Have a donor plan recently
  • Have participated in this trial
  • The researchers believe that anyone who is unfit to participate in this test will be involved
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Ammoxetine Hydrochloride Enteric-coated Tablets

    Drug: Ammoxetine Hydrochloride Enteric-coated Tablets

  • Placebo comparator
    Placebo Enteric-coated Tablets

    Drug: placebo enteric-coated tablets

Interventions

  • There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested

  • Drugplacebo enteric-coated tablets

    There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Event

    Incidence of Adverse Events that researchers determined clinical significance

    Time frame: 15 days

  2. Area under the plasma concentration time curve (AUC)

    The pharmacokinetics(PK) profile of Ammoxetine Hydrochloride Enteric-coated Tablets

    Time frame: 11 days

  3. Maximum concentration (Cmax)

    The pharmacokinetics(PK) profile of Ammoxetine Hydrochloride Enteric-coated Tablets

    Time frame: 11 days

  4. Half life Period (t1/2)

    The pharmacokinetics(PK) profile of Ammoxetine Hydrochloride Enteric-coated Tablets

    Time frame: 11 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2019; primary completion for May 2019, 2 months later.

Of 102 phase 1 interventional studies under Depression, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 22, 2019
StartEst.
Mar 10, 2019
Primary completionEst.
May 31, 2019
CompletionEst.
Oct 31, 2019
Last update
Feb 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03850834
Responsible party
Sponsor
First posted
Feb 22, 2019
Start date
Mar 10, 2019 (estimated)
Primary completion
May 31, 2019 (estimated)
Completion
Oct 31, 2019 (estimated)
Last update
Feb 22, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ammoxetine

Start the discussion